

PRESS RELEASE – FOR IMMEDIATE DISTRIBUTION

IntegraGen Reports Financial Results for 1st Half of 2017

Financial results

- Revenues: 3.1 M€, up 7% vs. H1 2016
- Significant growth in clinical genomics services: + 36%
- Operating income: -1.2 M€, stable vs. H1 2016
- Net income: -0.5 M€ vs. -1.1 M€ in H1 2016

Major advances in diagnostics activity

- 1st licensing agreement with Laboratoire Cerba for the commercialization of a diagnostic test in metastatic colorectal cancer
- CE-IVD labeling of a diagnostic kit measuring miR-31-3p, a predictive marker of response to anti-EGFR therapy

ÉVRY, FRANCE (29 September 2017) - IntegraGen (FR0010908723 – ALINT – Eligible PEA PME), a company specializing in the transformation of data from biological samples into genomic information and diagnostic tools for oncology, today announced its results for the first half of 2017. The financial statements were validated by the Company's Board of Directors on September 28, 2017.

KEY INDICATORS -in thousand EUROS	H1 2017 (6 months)	H1 2016 (6 months)	Var. %
Sales	3,089	2,880	+7%
Total revenues	3,294	3,034	+9%
EBIT	(1,248)	(1,152)	(8%)
Net results	(480)	(1,028)	+53%
	June 30, 2017	December 31, 2016	
CASH POSITION -in thousand EUROS	4 376	2 727	+60%

Bernard Courtieu, IntegraGen's Chairman and Chief Executive Officer said: "Several major milestones were reached during the first half of 2017, consolidating our reserves for future growth: the first was reaching a licensing agreement with Cerba Laboratories for our miR-31-3p biomarker, obtaining CE-IVD marking for our miRpredX 31-3p test and the renewal of our agreements with Gustave Roussy, the largest center for the fight against cancer in Europe. In addition to the significant improvement in our revenues, our operating income was stable despite operational efforts initiate production of our miRpredX 31-3p kit. As a result of these advances, we remain fully confident in the dynamics of our business development, both with our diagnostic and genomic activities, and look forward to obtaining the first results associated with our software for interpreting genomic data."

FINANCIAL INFORMATION

INCOME STATEMENT

Sales revenue for the first half of 2017 amounted to 3,089 thousand euros compared to 2,880 thousand euros during the same period in 2016. After taking into account operating subsidies and reversals of depreciation and amortization, and provisions, operating income improved to 3,294 thousand euros compared to 3,034 thousand euros in the first half of 2016, an improvement of 9%.

Operating expenses totaled 4,542 thousand euros, an increase of 8% compared to the first half of 2016. This increase was primarily due to the specific development costs of the miRpredX 31-3p diagnostic kit.

Operating income amounted to a loss of 1,248 thousand euros during the first half of 2017, compared to a loss of 1,152 thousand euros in the first half of 2016. As previously stated, the operating loss reported includes most of the expenses related to the implementation of the miRpredX kit manufacturing facility and the associated cost of launching the kit. This demonstrates the ability to control costs.

Net financial income was positive at 21 thousand euros.

During the period, the Company recorded an exceptional loss of 498 thousand euros, related in part to the waiver of BPI's claim for 600 thousand euros. In the first half of 2016, the exceptional result was a loss of 76 thousand euros.

After taking into account the financial and exceptional results and the research tax credit (CIR) related to the research carried out during the period, the **net result** showed a loss of 480 thousand euros, compared to a loss of 1,028 thousand euros in the first half of 2016.

BALANCE SHEET

The net cash position of IntegraGen amounted to 4,376 thousand euros at the end of June 2017, compared to 2,727 thousand euros at the end of December 2016.

In February 2017, the Company completed a capital increase of 3.7 M€ in connection with a private placement. During the first half of 2017, cash consumption amounted to 1,859 thousand euros compared with 1,238 thousand euros during the same period in 2016. This increase was primarily due to the repayment of BPI advances in the amount of 300 thousand euros and the receivable of the research tax credit settled in July 2017 when it had been received as of June in 2016.

KEY ACTIVITIES

Genomic Services

IntegraGen's sales year to date amounted to 3.0 M€ as of June 30, 2017, an increase of 3% compared to the first half of 2016. In the "clinical" segment, growth was 36%. Gustave Roussy and IntegraGen renewed their current contract for an additional three years. In the "Research" segment, sales were down slightly due to a technical downturn in June 2017, while orders in this segment showed an increase.

Software

Advances in the development of the Interpretation of Clinical Exome (ICE) interpretive software has led to the launch of a beta test with several clinicians during the first half of the year. A commercial version will be available in 2018.

Diagnosics

As a result of several scientific studies completed since 2011, IntegraGen has validated the association between the expression of the microRNA miR-31-3p marker and the efficacy of anti-EGFR treatment in patients with metastatic colon cancer.

Operational and commercial activities resulting from this research were initiated in 2017. The Company has entered into a licensing agreement with Laboratoire Cerba to provide this diagnostic test to customers for metastatic colorectal cancer. Royalties at the end of June amounted to € 0.1 million. In September 2017, the Company announced the CE-IVD marking of the "miRpredX" 31-3p kit, with an industrial production project for the kit launched at the end of 2016. This kit is intended primarily for the European market.



About IntegraGen

IntegraGen is a company specializing in deciphering the human genome and producing relevant and easily interpretable data for academic and private laboratories. IntegraGen's oncology efforts provide researchers and clinicians with sophisticated tools for analysis and therapeutic individualization of treatment approaches allowing them to tailor therapy to the genetic profiles of patients. As of December 31, 2016, IntegraGen had 38 employees and had generated revenue of €6.0 million in 2016. Based in Evry Genopole, IntegraGen also has an U.S. office in Cambridge, Massachusetts. IntegraGen is listed on Euronext Growth (ISIN: FR0010908723 - Ticker: ALINT - PEA-SME).

For more information, visit www.integragen.com

CONTACTS

IntegraGen

Bernard COURTIEU
President and CEO

Laurence RIOT LAMOTTE
Chief Financial Officer
contact@integragen.com
Tel.: +33 (0)1 60 91 09 00



NewCap

Investor and Media Relations
Louis-Victor DELOUVRIER
integragen@newcap.eu
Tel.: +33 (0)1 44 71 98 53

FINANCIAL STATEMENTS AS OF JUNE 30, 2017

P & L – INTEGRAGEN SA

<i>in K€</i>	6/30/2017	6/30/2016	Var. %
Revenues	3,089	2,880	+7%
Operating subsidies and other revenue	206	154	<i>ns</i>
Total revenue	3,294	3,034	+9%
Operating costs	(4,542)	(4,186)	(8%)
Operating profit	(1,248)	(1,152)	(8%)
Financial profit/loss	21	52	<i>n/a</i>
Current results	(1,227)	(1,150)	(7%)
Exceptional profit/loss	(498)	(76)	<i>n/a</i>
Taxes (CIR)	249	149	+67%
Net result	(480)	(1,028)	+53%

BALANCE SHEET – INTEGRAGEN SA

<i>in K€</i>	6/30/2017	12/31/2016	Var. %
Long-term assets	1,201	1,502	(20%)
Stocks	373	378	(1%)
Accounts receivable	1,859	2,140	(13%)
Other receivables	1,066	821	+30%
Cash	4,376	2,727	+60%
Current assets	7,674	6,065	+27%
Translation difference		22	<i>ns</i>
TOTAL ASSETS	8,874	7,590	+17%

<i>in K€</i>	6/30/2017	12/31/2016	Var. %
Shareholders' equity	4,313	1,282	<i>ns</i>
Conditioned advance payment	592	1,492	(60%)
Reserve	2	36	<i>ns</i>
Notes payable to banks		0	<i>n/a</i>
Accounts payable	2,494	3,023	(18%)
Other short-term debt	1,003	1,088	
Translation difference	469	667	(30%)
TOTAL LIABILITIES	8,874	7,590	+17%